Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.
Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 7 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
Y-biologics: A Phase 1, Open-Label, Multicenter, Single Arm, Dose-Escalation/Dose-Expansion Study of YBL-006 in Patients with Advanced Solid Tumors
Sabanathan, D., Park, J., Gurney, H., Chapman, N. & Rai, M.
1/06/20 → 30/04/23
Project: Research
COSMIC: A randomized, double-blind, controled phase 3 study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate to poor risk
Gurney, H., Butala, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
2/10/19 → 11/07/24
Project: Other
COSMIC: A randomized, double-blind, controled phase 3 study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate to poor risk
Gurney, H., Butala, R., Chapman, N., Parshionikar, A. & Rajasekharan Nair, A.
2/10/19 → 11/07/24
Project: Other
Harbour Biomed 4003.1: A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors
Gurney, H., Chapman, N., Butala, R., Parshionikar, A. & Rajasekharan Nair, A.
30/09/19 → 30/09/24
Project: Other
KEYNOTE-641: Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Gurney, H., Chapman, N. & Butala, R.
8/08/19 → 5/06/24
Project: Other
Research Outputs
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
Sternberg, C. N., Saad, F., Graff, J. N., Peer, A., Vaishampayan, U. N., Leung, E., Rosenbaum, E., Gurney, H., Epstein, R. J., Davis, I. D., Wu, B., Trandafir, L., Wagner, V. J. & Hussain, M., 1 Feb 2020, In : Annals of Oncology. 31, 2, p. 257-265 9 p.Research output: Contribution to journal › Article
Open Access
File
1
Citation
(Scopus)
Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma
Bhatnagar, A., McKay, M. J., Arasaratnam, M., Crumbaker, M., Gurney, H. & Molloy, M. P., 31 May 2020, (Accepted/In press) In : Journal of Mass Spectrometry.Research output: Contribution to journal › Article
Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics
Nath, C. E., Trotman, J., Nivison-Smith, I., Gurney, H., Zeng, L., Presgrave, P., Tiley, C., Joshua, D., Kerridge, I., McLachlan, A. J. & Shaw, P. J., 21 Feb 2020, In : Bone Marrow Transplantation. 3 p.Research output: Contribution to journal › Letter
The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training
Lam, T., Birzniece, V., McLean, M., Gurney, H., Hayden, A. & Cheema, B. S., 13 Feb 2020, In : Sports Medicine - Open. 6, 1, p. 1-14 14 p., 13.Research output: Contribution to journal › Review article
Open Access
File
The AGITG GAP Study: a Phase II study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer
Barbour, A. P., Samra, J. S., Haghighi, K. S., Donoghoe, M. W., Burge, M., Harris, M. T., Chua, Y. J., Mitchell, J., O’Rourke, N., Chan, H., Gebski, V. J., Gananadha, S., Croagh, D. G., Kench, J. G., Goldstein, D. & Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators, 1 Jul 2020, In : Annals of Surgical Oncology. 27, 7, p. 2506-2515 10 p.Research output: Contribution to journal › Article